Other
Drug-Induced Liver Injury
15
Pipeline Programs↗
1
Active Trials↗
8
Companies Involved↗
Drug-Induced Liver Injury is an emerging landscape with 15 programs across 8 companies. The most active players are Teva, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Mission Pharmacal. 9 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 11
Phase 23
Phase 32
Analysis
Trial Status
9
clinical trials
Unknown status4 · 44%
Completed4 · 44%
Not yet recruiting1 · 11%
Clinical Trials
Trial Activity
9 trials
Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease
Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·Phase 2/3·NCT06797011·96 enrolled
Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.
Unknown status·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT05711459·5,405 enrolled
Glucocorticosteroid Therapy on Drug-induced Liver Injury: a Prospective Non-randomized Concurrent Control Trial
Unknown status·—·Phase 4·NCT04553003·80 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)